Oslo, Norway, 22 July 2025: Photocure ASA (Photocure, PHO: OSE) will announce
the second quarter and first half year 2025 financial results on Wednesday 30
July 2025 at 07:00 CEST and will present a live webcast at 14:00 CEST the same
day.
The quarterly report and presentation will be published at 07:00 CEST and will
be publicly available at www.photocure.com.
The investor presentation will be streamed live and be hosted by Dan Schneider,
CEO and Erik Dahl, CFO. The presentation will be held in English and questions
can be submitted throughout the event. The presentation is scheduled to conclude
at 14:45 CEST.
The streaming event is available through
https://channel.royalcast.com/landingpage/hegnarmedia/20250730_1/ (https://eur01.
safelinks.protection.outlook.com/?url=https%3A%2F%2Fchannel.royalcast.com%2Flandi
ngpage%2Fhegnarmedia%2F20250730_1%2F&data=05%7C02%7CTH%40photocure.no%7C3ce06316f
ae04d9c170f08ddc7ad22ee%7C0986794f1d6f488980bd853c0715d3c1%7C0%7C0%7C638886268625
978184%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOi
JXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=3lsIp5FD6yFKtE2HpQl
lIFd%2Bi%2F4bojLig8ei%2B2JdLb8%3D&reserved=0)
For further information, please contact:
Photocure
Erik Dahl
CFO
Tel: +47 45055000
Email: ed@photocure.com
Jonas Fougner
Interim IRO
Tel: +47 94805851
Email: jonas.fougner@photocure.com
Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway) Tel: +47 91540000
Email: geir.bjorlo@corpcom.no
About Photocure
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.cysview.com
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.